DK3207053T3 - Hidtil ukendte immunogene peptider - Google Patents
Hidtil ukendte immunogene peptider Download PDFInfo
- Publication number
- DK3207053T3 DK3207053T3 DK15787917T DK15787917T DK3207053T3 DK 3207053 T3 DK3207053 T3 DK 3207053T3 DK 15787917 T DK15787917 T DK 15787917T DK 15787917 T DK15787917 T DK 15787917T DK 3207053 T3 DK3207053 T3 DK 3207053T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunogenic peptides
- new immunogenic
- new
- peptides
- immunogenic
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1418433.7A GB201418433D0 (en) | 2014-10-17 | 2014-10-17 | Novel immunogenic peptides |
| PCT/EP2015/074063 WO2016059236A1 (en) | 2014-10-17 | 2015-10-16 | Novel immunogenic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3207053T3 true DK3207053T3 (da) | 2019-11-04 |
Family
ID=52013133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15787917T DK3207053T3 (da) | 2014-10-17 | 2015-10-16 | Hidtil ukendte immunogene peptider |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180228912A1 (da) |
| EP (2) | EP3207053B1 (da) |
| JP (2) | JP6655626B2 (da) |
| KR (1) | KR102556485B1 (da) |
| CN (1) | CN107148427B (da) |
| AU (2) | AU2015332621B2 (da) |
| BR (1) | BR112017007773A2 (da) |
| CA (1) | CA2964426C (da) |
| DK (1) | DK3207053T3 (da) |
| ES (1) | ES2751605T3 (da) |
| GB (1) | GB201418433D0 (da) |
| MX (1) | MX374635B (da) |
| PL (1) | PL3207053T3 (da) |
| PT (1) | PT3207053T (da) |
| RU (1) | RU2709711C2 (da) |
| WO (1) | WO2016059236A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| ES2545886T3 (es) | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| ES2924027T3 (es) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| US10653797B2 (en) | 2015-09-02 | 2020-05-19 | Sanford Burnham Prebys Medical Discovery Institute | Compounds and compositions for targeting brain injuries and methods of use thereof |
| JP7090335B2 (ja) | 2015-09-25 | 2022-06-24 | イムサイス エスエー | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 |
| AU2017252192C1 (en) | 2016-04-19 | 2023-06-08 | Imcyse Sa | Novel immunogenic CD1d binding peptides |
| EP3592765A1 (en) * | 2017-03-09 | 2020-01-15 | ImCyse SA | Peptides and methods for the treatment of diabetes |
| US11376303B2 (en) | 2017-12-07 | 2022-07-05 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for treating nervous system injuries |
| US20210401976A1 (en) | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| US20230113747A1 (en) | 2019-05-16 | 2023-04-13 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
| US20230136112A1 (en) | 2019-11-27 | 2023-05-04 | Imcyse Sa | Methods for stratifying diabetes patients |
| WO2021148683A2 (en) | 2020-05-06 | 2021-07-29 | Imcyse Sa | Peptides and methods for the treatment of multiple sclerosis |
| CN115867567A (zh) | 2020-05-06 | 2023-03-28 | 易姆赛斯股份公司 | 具有新氧化还原酶基序的免疫原性肽 |
| WO2021224397A1 (en) | 2020-05-06 | 2021-11-11 | Imcyse Sa | Immunogenic peptides with extended oxidoreductase motifs |
| EP4146190A2 (en) * | 2020-05-06 | 2023-03-15 | Imcyse SA | Combination treatment for fumarate-related diseases |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
| US20240150407A1 (en) * | 2021-04-09 | 2024-05-09 | Ajou University Industry-Academic Cooperation Foundation | Peptide for preventing or treating inflammatory diseases |
| MX2023013971A (es) | 2021-05-26 | 2023-12-11 | Imcyse Sa | Metodos para tratar o prevenir enfermedades autoinmunes. |
| KR20240015672A (ko) | 2021-06-01 | 2024-02-05 | 임시스 에스에이 | 면역원성 펩티드를 사용한 개선된 치료 방법 |
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
| US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| ATE238065T1 (de) | 1990-09-27 | 2003-05-15 | Tripep Ab | Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus |
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
| CA2350911A1 (en) | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
| US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| EP2311950A1 (en) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
| AU2001272491A1 (en) | 2000-06-26 | 2002-01-08 | Smithkline Beecham Biologicals (S.A.) | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| EP1409650B1 (en) | 2001-05-30 | 2006-04-12 | Fondazione Telethon | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| JP4537060B2 (ja) | 2001-10-03 | 2010-09-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 治療剤および他剤の送達のための炭水化物結合領域含有融合タンパク質、およびそれらを含む組成物 |
| AU2003215395A1 (en) | 2002-02-21 | 2003-09-09 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
| US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
| DK2261249T3 (da) | 2002-09-12 | 2015-02-16 | Oncotherapy Science Inc | KDR-peptider og vacciner omfattende det samme |
| US20070054262A1 (en) | 2003-03-28 | 2007-03-08 | Baker Denise M | Methods of identifying optimal variants of peptide epitopes |
| US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| AU2004281634B2 (en) | 2003-09-03 | 2011-01-27 | Dendritherapeutics, Inc. | Multiplex vaccines |
| GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
| WO2005042575A2 (en) | 2003-10-30 | 2005-05-12 | Pharmexa A/S | Method for down-regulation of vegf |
| US8202841B2 (en) | 2004-06-17 | 2012-06-19 | Mannkind Corporation | SSX-2 peptide analogs |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| US8486411B2 (en) | 2005-08-30 | 2013-07-16 | Children's Hospital & Research Center At Oakland | Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
| ES2709176T3 (es) * | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
| CA2700618A1 (en) | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| US9248171B2 (en) | 2008-02-14 | 2016-02-02 | Imcyse Sa | Immunogenic peptides and their use in transplantation |
| CA2715536C (en) | 2008-02-14 | 2018-01-16 | Life Sciences Research Partners Vzw | Cd4+ t-cells with cytolytic properties |
| ES2545886T3 (es) | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| EP2252329B1 (en) * | 2008-02-14 | 2015-06-17 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
| EP2249864B1 (en) | 2008-02-14 | 2016-05-04 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
| US9764012B2 (en) | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
| CN103002909B (zh) | 2010-03-29 | 2016-06-29 | 国家科学研究中心 | 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途 |
| ES2924027T3 (es) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| SG10201609500QA (en) | 2012-02-15 | 2016-12-29 | Ecole Polytech | Erythrocyte-binding therapeutics |
| US20150125880A1 (en) * | 2012-04-30 | 2015-05-07 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
| SG10201803780UA (en) | 2013-11-04 | 2018-06-28 | Uti Lp | Methods and compositions for sustained immunotherapy |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| JP7090335B2 (ja) | 2015-09-25 | 2022-06-24 | イムサイス エスエー | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 |
| AU2017252192C1 (en) | 2016-04-19 | 2023-06-08 | Imcyse Sa | Novel immunogenic CD1d binding peptides |
| EP3592765A1 (en) | 2017-03-09 | 2020-01-15 | ImCyse SA | Peptides and methods for the treatment of diabetes |
| US20210401976A1 (en) | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| US20230113747A1 (en) | 2019-05-16 | 2023-04-13 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
-
2014
- 2014-10-17 GB GBGB1418433.7A patent/GB201418433D0/en not_active Ceased
-
2015
- 2015-10-16 PT PT157879172T patent/PT3207053T/pt unknown
- 2015-10-16 ES ES15787917T patent/ES2751605T3/es active Active
- 2015-10-16 WO PCT/EP2015/074063 patent/WO2016059236A1/en not_active Ceased
- 2015-10-16 KR KR1020177012944A patent/KR102556485B1/ko active Active
- 2015-10-16 BR BR112017007773-6A patent/BR112017007773A2/pt active Search and Examination
- 2015-10-16 DK DK15787917T patent/DK3207053T3/da active
- 2015-10-16 US US15/516,045 patent/US20180228912A1/en not_active Abandoned
- 2015-10-16 EP EP15787917.2A patent/EP3207053B1/en active Active
- 2015-10-16 EP EP19192582.5A patent/EP3636666A1/en not_active Withdrawn
- 2015-10-16 MX MX2017004780A patent/MX374635B/es active IP Right Grant
- 2015-10-16 AU AU2015332621A patent/AU2015332621B2/en active Active
- 2015-10-16 RU RU2017111657A patent/RU2709711C2/ru active
- 2015-10-16 JP JP2017540316A patent/JP6655626B2/ja active Active
- 2015-10-16 CA CA2964426A patent/CA2964426C/en active Active
- 2015-10-16 PL PL15787917T patent/PL3207053T3/pl unknown
- 2015-10-16 CN CN201580056434.6A patent/CN107148427B/zh active Active
-
2019
- 2019-10-17 AU AU2019250206A patent/AU2019250206A1/en not_active Abandoned
-
2020
- 2020-02-03 JP JP2020016331A patent/JP2020079271A/ja active Pending
- 2020-06-04 US US16/892,588 patent/US12023384B2/en active Active
-
2024
- 2024-05-24 US US18/674,092 patent/US20240342297A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240342297A1 (en) | 2024-10-17 |
| PT3207053T (pt) | 2019-11-15 |
| BR112017007773A2 (pt) | 2018-01-16 |
| MX374635B (es) | 2025-03-06 |
| EP3207053B1 (en) | 2019-08-21 |
| CA2964426A1 (en) | 2016-04-21 |
| JP2020079271A (ja) | 2020-05-28 |
| PL3207053T3 (pl) | 2020-05-18 |
| US20200397911A1 (en) | 2020-12-24 |
| AU2015332621B2 (en) | 2019-07-18 |
| EP3207053A1 (en) | 2017-08-23 |
| RU2017111657A (ru) | 2018-11-19 |
| EP3636666A1 (en) | 2020-04-15 |
| RU2709711C2 (ru) | 2019-12-19 |
| RU2017111657A3 (da) | 2019-05-29 |
| JP2018504419A (ja) | 2018-02-15 |
| KR20170069266A (ko) | 2017-06-20 |
| KR102556485B1 (ko) | 2023-07-17 |
| AU2015332621A1 (en) | 2017-04-13 |
| CA2964426C (en) | 2023-01-24 |
| JP6655626B2 (ja) | 2020-02-26 |
| US20180228912A1 (en) | 2018-08-16 |
| MX2017004780A (es) | 2017-11-30 |
| ES2751605T3 (es) | 2020-04-01 |
| US12023384B2 (en) | 2024-07-02 |
| GB201418433D0 (en) | 2014-12-03 |
| CN107148427A (zh) | 2017-09-08 |
| CN107148427B (zh) | 2021-08-13 |
| AU2019250206A1 (en) | 2019-11-07 |
| WO2016059236A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3207053T3 (da) | Hidtil ukendte immunogene peptider | |
| DK3393510T5 (da) | Zikavirusvaccine | |
| DK3234128T3 (da) | Sekventeringskontroller | |
| DK3171891T3 (da) | Fremgangsmåde | |
| DK3102669T3 (da) | Forbedret bacillevært | |
| DK3218504T3 (da) | Trisegmenterede arenavira som vaccinevektorer | |
| HUE042087T2 (hu) | Inhalátor | |
| DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
| CL2016002146A1 (es) | Plásmidos inmunoestimuladores | |
| IL250502A0 (en) | New polypeptides | |
| DE112015001664A5 (de) | Betätigungsaktuator | |
| DK3099791T3 (da) | Protein | |
| DK3164410T3 (da) | Protein-indvinding | |
| HRP20182029T1 (hr) | Uti-fuzijski proteini | |
| DK3522905T3 (da) | Immunogene arginasepeptider | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| DK3099793T3 (da) | Protein | |
| DK3228706T3 (da) | Coekspressionsplasmid | |
| HUE047581T2 (hu) | Készítmény | |
| ME03083B (me) | Veštački sfinkter | |
| LT3188755T (lt) | Vakcina | |
| DE112015001633A5 (de) | Betätigungsaktuator | |
| DK3319625T3 (da) | Immunogene præ-procalcitoninpeptider | |
| ES2775740T8 (es) | Péptidos | |
| ES1133956Y (es) | Parasol |